Final Results from the Phase I Study Expansion Cohort of Debio 0932, an Oral HSP90 Inhibitor, in Patients with Solid Tumors

Presented at ASCO 2014, Chicago, USA

P Fumoleau (1), J-C Soria (2), J-P Delord (3), R Belli (4), S Brienza (4), C Zanna (4), A Destaillats (4), E Rouits (4), A Hollebecque (2), A Gazzah (2), N Isambert (1)

1. Centre Georges François Leclerc, Dijon, France
2. Institut Gustave Roussy, Villejuif, France
3. Institut Claudius Regaud, Toulouse, France
4. Debiopharm International SA, Lausanne, Switzerland